Observe Medical ASA · OSL:OBSRV
Observe Medical ASA — Q1 2021 Earnings Presentation
32 slides from Observe Medical ASA's earnings presentation, May 12, 2021
Slide 1: Observe Medical Q1 2021
OBSERVE MEDICAL Q1 2021 CEO Björn Larsson / CFO Per Arne Nygård Oslo, May 12, 2021
Slide 2: Overview
OBSERVE MEDICAL Overview Nordic based medtech company with global reach Solid platform for growth, commercializing innovative medtech products on a global market –by organic growth and targeted M&A. Nordic direct sales organization with strong customer and supplier relations, and an expanding distri
Slide 3: Covid-19 business impact
OBSERVE MEDICAL Covid-19 business impact Q1 2021 Currently Onwards Covid-19 policies in place and operations as normal, digital team interactions During the less severe period, Q4 2020-Q1 2021, several Pandemics is again in a phase Current focus is clinical clinical sites initiated with severe workl
Slide 4: The 2021 year to date journey
OBSERVE MEDICAL Overview The 2021 year to date journey Further strengthening of the sales organization in the Solid medtech platform for growth Nordics ~15 new Sippi® systems Expanded and strengthened Sippi® delivered to clinical sites the global patent protection Automated and wireless connected di
Slide 5: Sippi - the first automated digital urine meter with biofilm control
Sippi® - the first automated digital urine meter with biofilm control • Sippi® - the first automated digital urine meter with biofilm control 7
Slide 6: Hourly urine monitoring is one of the last remaining manual procedures
Hourly urine monitoring of patients is one of the last remaining manual monitoring procedures in the ICU with significant clinical implications Inaccurate patient data for clinical decisions Time-consuming for staff and compromised ergonomics - reducing clinical capacity Risk of infections - risk fo
Slide 7: Sippi addresses the clinical challenges
… and Sippi® addresses the clinical challenges Only automated, digital urine meter with wireless data transfer (Sipplink®) to the hospital patient data management system and which detects (Sippsense®) and hinders (Sippcoat®) bacterial biofilm formation – that can lead to urinary infections. Improved
Slide 8: New study with aim to broaden the clinical scope of Sippi
SIPPI® New study with aim to broaden the clinical scope of Sippi® New study at Nya Karolinska Advisory Board supports Recent doctoral dissertation further Sjukhuset, led by Professor Jan demonstrates clinical benefits of Sippi® Sippi® clinical and commercial van der Linden, has in May opportunity 20
Slide 9: Sippi Market Opportunity
SIPPI® MARKET OPPORTUNITY Addressing a substantial market supported by key market drivers and COVID-related impact Current market Sippi® value and potential accentuated by market trends and pandemic CURRENT MARKET POTENTIAL ICU CAPABILITIES VOLUME GROWTH SIPPI® VALUE FURTHER ACCENTUATED 4 bn NOK ~0,
Slide 10: Global launch: current focus clinical roll-out
Global launch Current focus: Broader EU launch Clinical roll-out – in Nordics and selected European markets
Slide 11: Accelerating Sippi rollout when pandemic eases
Current focus: Clinical roll-out – in Nordics and selected European markets Accelerating Sippi® rollout when pandemics eases later in 2021 Insights and learnings during the pandemic: • On-site training is essential for successful Sippi® implementation Use the insights to prepare • Increased patient
Slide 12: Global launch: current focus broader EU launch
Global launch Current focus: Broader EU launch Clinical roll-out – in Nordics and selected European markets Use the insights to prepare – accelerating rollout of Sippi® when customer access regained
Slide 13: Financial Review
FINANCIAL REVIEW CFO Per Arne Nygård
Slide 14: Revenue and Gross Results Q1 2021
FINANCIAL REVIEW Revenue and Gross Results Q1 2021 Revenues Revenue and gross results Revenue breakdown by category • Total revenues at TNOK Amount in TNOK 3 110 Amounts in TNOK 3 110 Gross • Extensive sales activities margin: in the quarter, which will 27.1% give revenue growth in 844 Q2 and Q3 506
Slide 15: Key Figures - Profit and Loss Statement
FINANCIAL REVIEW Key Figures - Profit and Loss Statement Operating expenses • Increased headcount Amount in TNOK (excl. earnings per share) Q1 2021 Q1 2020 FY 2020 mainly due to acquisition of Sylak and Gross result 844 -27 986 new recruitments from Operating expenses 8 859 4 383 25 910 January 1, 2
Slide 16: Key Figures - Statement of Financial Position
FINANCIAL REVIEW Key Figures - Statement of Financial Position (Amount in TNOK) At 31 March 2021 At 31 March 2020 At 31 December 2020 Assets ASSETS Non-current assets Goodwill 33 933 33 430 36 268 Increased inventories and Intangible assets and tangible assets 20 710 22 894 21 668 receivables mainly
Slide 17: Key Figures - Cash Flow Statement Q1 2021
FINANCIAL REVIEW Key Figures - Cash Flow Statement Q1 2021 Cash flow used in operating activities due to: (Amount in TNOK) • Result in the period • Increased receivables due to prepayment to supplier for materials for sale in Q2. 18,946 -10,781 • Decreased trade payables and other current liabilitie
Slide 18: Summary and Outlook
SUMMARY AND OUTLOOK CEO Björn Larsson
Slide 19: Summary & Outlook
OBSERVE MEDICAL Summary & Outlook Summary Outlook Continued rollout of Sippi® systems in clinical use, Continuous roll-out of Sippi® despite restricted customer access during Covid-19 systems for clinical use Increased customer interaction generates feedback Expanding the distributor for commercial
Slide 20: Q&A
Q&A
Slide 21: Thank you!
Thank you!
Slide 22: Appendix
Appendix
Slide 23: Finance calendar
OBSERVE MEDICAL Finance calendar 20 August Presentation of Q2 and first half year 2021 21 May 3 November Annual General Meeting Presentation of Q3 2021
Slide 24: Experienced management team and board
OBSERVE MEDICAL Experienced management team and board Management team Björn Larsson Per Arne Nygård Mikael Löfgren Anders Nachtweij Chief Executive Officer Chief Financial Officer CTO/COO Sales Director Board of directors Terje Bakken Kristin Nyberg Kathrine Gamborg Andreassen Thomas Grünfeld Chairm
Slide 25: Condensed Consolidated Statement of Comprehensive Income
(UNAUDITED FOR THE PERIOD ENDED 31 MARCH) Condensed Consolidated Statement of Comprehensive Income (Amounts in NOK) Q1 2021 Q1 2020 FY 2020 Operating revenues 3 109 505 32 220 2 961 334 Cost of materials 2 265 385 59 320 1 975 121 Gross result 844 121 -27 100 986 212 Employee benefit expenses 4 124
Slide 26: Condensed Consolidated Statement of Financial Position
(UNAUDITED FOR THE PERIOD ENDED 31 MARCH 2021) Condensed Consolidated Statement of Financial Position (Amounts in NOK) At 31 March 2021 At 31 March 2020 At 31 December 2020 ASSETS Non-current assets Goodwill 33 932 687 33 430 414 36 268 318 Intangible assets 19 520 998 22 641 708 20 965 076 Tangible
Slide 27: Condensed Consolidated Statement of Financial Positions
(UNAUDITED FOR THE PERIOD ENDED 31 MARCH 2021) Condensed Consolidated Statement of Financial Positions (Amounts in NOK) At 31 March 2021 At 31 March 2020 At 31 December 2020 EQUITY AND LIABILITIES Total equity 6 631 933 14 640 759 20 349 125 Non-current liabilities Non-current lease liabilities 609
Slide 28: Cash Flow Statement
(UNAUDITED FOR THE PERIOD ENDED 31 MARCH 2021) Cash Flow Statement (Amounts in NOK) Q1 2021 Q1 2020 FY 2020 Cash flow from operating activities Result before tax -4 818 799 -423 943 -36 868 470 Depreciation and impairment 797 637 778 578 3 163 304 Change in net finance, no cash effect -4 065 382 -5
Slide 29: Top 20 Shareholders
AS OF MAY 4, 2021 Top 20 Shareholders Rank Name Number of shares % of top 20 % of total Country 1 NAVAMEDIC ASA 4 222 727 25,14 % 21,54 % Norway 2 INGERØ REITEN INVESTMENT COMPANY 3 939 394 23,45 % 20,09 % Norway 3 RO, LARS 1 500 051 8,93 % 7,65 % Norway 4 UBS Switzerland AG 1 417 522 8,44 % 7,23 %
Slide 30: Definitions of Alternative Performance Measures (APM)
OBSERVE MEDICAL Definitions of Alternative Performance Measures (APM) The APMs are regularly reviewed by management and their aim is to enhance stakeholders’ understanding of the company’s performance. APMs presented may be determined or calculated differently by other companies. Gross result: Opera
Slide 31: Copyright and Disclaimer
OBSERVE MEDICAL Copyright and Disclaimer Copyright Disclaimer reliability or completeness of the Copyright of all published material This Presentation includes and is based, Presentation, and neither Observe Medical including photographs, drawings inter alia, on forward-looking information ASA nor a
Slide 32: oKeonserve
oKeonserve Taaexe |(er=l|